218 related articles for article (PubMed ID: 33030432)
21. Isolated CNS involvement in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: A case report.
Son H; Lee WJ; Moon J; Yoon S; Jung KH; Park KI; Lee SK; Chu K
J Neuroimmunol; 2021 Jun; 355():577551. PubMed ID: 33773378
[TBL] [Abstract][Full Text] [Related]
22. Benralizumab in Real Life.
Miralles López JC; Escudero Pastor AI; Carbonell Martínez A; Navarro Garrido C; Bonilla Pacheco Y; Petrik Petrik Y
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):87-88. PubMed ID: 32573458
[No Abstract] [Full Text] [Related]
23. Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis.
Matsuno O; Minamoto S
Respir Med Case Rep; 2022; 40():101763. PubMed ID: 36353062
[TBL] [Abstract][Full Text] [Related]
24. Benralizumab for the treatment of asthma.
Matera MG; Rogliani P; Calzetta L; Canonica GW; Cazzola M
Drugs Today (Barc); 2017 Dec; 53(12):633-645. PubMed ID: 29517082
[TBL] [Abstract][Full Text] [Related]
25. Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.
Kim JE; Lee DH; Jung K; Kim EJ; Choi Y; Park HS; Kim YS
Front Immunol; 2020; 11():593748. PubMed ID: 33488590
[TBL] [Abstract][Full Text] [Related]
26. Benralizumab in eosinophilic granulomatosis with polyangiitis.
Laorden D; Romero D; Domínguez-Ortega J
Med Clin (Barc); 2022 May; 158(9):441-442. PubMed ID: 34728088
[No Abstract] [Full Text] [Related]
27. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
[TBL] [Abstract][Full Text] [Related]
28. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Sun R; Wei LJ
N Engl J Med; 2024 May; 390(20):1939. PubMed ID: 38810203
[No Abstract] [Full Text] [Related]
29. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
Laviolette M; Gossage DL; Gauvreau G; Leigh R; Olivenstein R; Katial R; Busse WW; Wenzel S; Wu Y; Datta V; Kolbeck R; Molfino NA
J Allergy Clin Immunol; 2013 Nov; 132(5):1086-1096.e5. PubMed ID: 23866823
[TBL] [Abstract][Full Text] [Related]
30. Mepolizumab for the Treatment of Eosinophilic Granulomatosis With Polyangiitis: Our Experience.
Díaz Campos RM; Prudencio Ribera VC; García Moguel I; Fernández-Rodríguez C; Corral Blanco M; Jarrin Estupiñan ME; Melero Moreno C
J Investig Allergol Clin Immunol; 2019 Oct; 29(5):384-385. PubMed ID: 31621630
[No Abstract] [Full Text] [Related]
31. Unsustained Response to Benralizumab in Eosinophilic Asthma After 3 Years of Therapy With Mepolizumab.
Kurosawa M; Shimizu Y; Sutoh Y; Sutoh E
J Investig Allergol Clin Immunol; 2021 Jul; 31(4):353-355. PubMed ID: 33136004
[No Abstract] [Full Text] [Related]
32. Benralizumab in the management of rare primary eosinophilic lung diseases.
Griscti Soler D; Bennici A; Brunetto S; Gangemi S; Ricciardi L
Allergy Asthma Proc; 2022 Nov; 43(6):494-500. PubMed ID: 36335418
[No Abstract] [Full Text] [Related]
33. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials.
Tian BP; Zhang GS; Lou J; Zhou HB; Cui W
J Asthma; 2018 Sep; 55(9):956-965. PubMed ID: 29211545
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.
Raffray L; Guillevin L
Drugs; 2018 Jun; 78(8):809-821. PubMed ID: 29766394
[TBL] [Abstract][Full Text] [Related]
36. A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related disease.
Kanda R; Kubo S; Nakano K; Kawabe A; Nawata A; Hanami K; Nakayamada S; Tanaka Y
Mod Rheumatol Case Rep; 2020 Jul; 4(2):278-282. PubMed ID: 33087011
[TBL] [Abstract][Full Text] [Related]
37. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
Nagase H; Ueki S; Fujieda S
Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
[TBL] [Abstract][Full Text] [Related]
38. The spectrum of therapeutic activity of mepolizumab.
Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
[No Abstract] [Full Text] [Related]
39. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study.
Detoraki A; Di Capua L; Varricchi G; Genovese A; Marone G; Spadaro G
J Asthma; 2016; 53(2):201-6. PubMed ID: 26377630
[TBL] [Abstract][Full Text] [Related]
40. A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.
Quan MV; Frankel SK; Maleki-Fischbach M; Tan LD
BMC Pulm Med; 2018 Nov; 18(1):181. PubMed ID: 30497438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]